tetano
Editor, Senior Moderator
Ann Med Surg (Lond)
. 2022 May;77:103657.
doi: 10.1016/j.amsu.2022.103657. Epub 2022 Apr 21.
Myocarditis after BNT162b2 and mRNA-1273 COVID-19 vaccination: A report of 7 cases
Sirwan Khalid Ahmed[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background and objectives: According to some reports, there is a link between the development of myocarditis and the administration of messenger RNA (mRNA) vaccines against coronavirus disease (COVID-19). Here, we report seven cases that developed myocarditis after receiving a second dose of mRNA COVID-19 vaccine.
Methods: This is a multi-center case series study. In this study, we present 7 patients diagnosed with myocarditis following BNT162b2 and mRNA-1273 COVID-19 vaccinations on March 7, 2021, and March 3, 2022.
Results: All seven patients were males and hemodynamically stable. The median age was 24.5 years, ranging from 16 to 36 years old. All patients received the second dose of a messenger RNA (mRNA) vaccine between one and four days before being admitted to the hospital (5 received BNT162b2 [Pfizer-BioNTech] and 2 received mRNA-1273 [Moderna]). The electrocardiograms of all seven patients were abnormal, and their troponin levels were elevated. Moreover, all patients were treated with colchicine and NSAIDs. The average length of stay in the hospital was 2.4 days, and all of the patients' symptoms had resolved by the time they were discharged.
Conclusion: The results of the current study raise the possibility of an association between BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna] COVID-19 vaccination and myocarditis.
Keywords: BNT162b2; COVID-19 vaccine; Myocarditis; mRNA vaccine; mRNA-1273.
. 2022 May;77:103657.
doi: 10.1016/j.amsu.2022.103657. Epub 2022 Apr 21.
Myocarditis after BNT162b2 and mRNA-1273 COVID-19 vaccination: A report of 7 cases
Sirwan Khalid Ahmed[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35479661
- PMCID: PMC9021031
- DOI: 10.1016/j.amsu.2022.103657
Abstract
Background and objectives: According to some reports, there is a link between the development of myocarditis and the administration of messenger RNA (mRNA) vaccines against coronavirus disease (COVID-19). Here, we report seven cases that developed myocarditis after receiving a second dose of mRNA COVID-19 vaccine.
Methods: This is a multi-center case series study. In this study, we present 7 patients diagnosed with myocarditis following BNT162b2 and mRNA-1273 COVID-19 vaccinations on March 7, 2021, and March 3, 2022.
Results: All seven patients were males and hemodynamically stable. The median age was 24.5 years, ranging from 16 to 36 years old. All patients received the second dose of a messenger RNA (mRNA) vaccine between one and four days before being admitted to the hospital (5 received BNT162b2 [Pfizer-BioNTech] and 2 received mRNA-1273 [Moderna]). The electrocardiograms of all seven patients were abnormal, and their troponin levels were elevated. Moreover, all patients were treated with colchicine and NSAIDs. The average length of stay in the hospital was 2.4 days, and all of the patients' symptoms had resolved by the time they were discharged.
Conclusion: The results of the current study raise the possibility of an association between BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna] COVID-19 vaccination and myocarditis.
Keywords: BNT162b2; COVID-19 vaccine; Myocarditis; mRNA vaccine; mRNA-1273.